Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2007 1
2008 2
2009 1
2010 4
2011 4
2012 8
2013 12
2014 11
2015 13
2016 12
2017 10
2018 2
2019 4
2020 1
2021 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 26722080

83 results

Results by year

Filters applied: . Clear all
Page 1
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S. Nishiyama A, et al. Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25. Lung Cancer. 2015. PMID: 26141215
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, Takeuchi Y, Kida H, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I. Minami S, et al. Lung Cancer. 2013 Nov;82(2):271-5. doi: 10.1016/j.lungcan.2013.07.022. Epub 2013 Aug 6. Lung Cancer. 2013. PMID: 23993733 Clinical Trial.
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V. Karampeazis A, et al. Cancer. 2013 Aug 1;119(15):2754-64. doi: 10.1002/cncr.28132. Epub 2013 May 9. Cancer. 2013. PMID: 23661337 Free article. Clinical Trial.
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Ciuleanu T, et al. Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24. Lancet Oncol. 2012. PMID: 22277837 Clinical Trial.
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Gautschi O, et al. Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5. Clin Lung Cancer. 2015. PMID: 25843489 Clinical Trial.
83 results